The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about the study, please email [email protected] or call 312-355-5112.
A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair
https://clinicaltrials.gov/ct2/show/NCT03810105
Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigator: Michael Abern, MD